Is Merck the Next Big Weight-Loss Stock?
Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just ...
Pharmabiz1d
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer: London Saturday, December 21, 2024, 17:30 ...
Why Viking Therapeutics Tumbled by More Than 10% This Week
According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period ...
MM&M2d
Rx Rundown: Sanofi, Novartis, Roche and more
The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...
Hosted on MSN2d
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) ...
FiercePharma2d
Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...
Becker's Hospital Review3d
Merck enters $2B licensing deal for weight loss drug
Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.
Hosted on MSN3d
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational ...
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time
Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...
devdiscourse3d
Breaking Health News: Major Approvals and Controversies in Pharma Industry
Merck has entered a $2 billion licensing deal with China's Hansoh Pharma for an oral weight-loss drug, positioning itself ...
thedailyupside4d
Merck Cautiously Enters GLP-1 Fray Via Licensing Deal With Chinese Drugmaker
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...
Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else
Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...